Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 2

1(33.3%)

Phase 1

1(33.3%)

3Total

N/A(1)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02735252Not ApplicableActive Not Recruiting

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Role: collaborator

NCT03061305Terminated

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Role: lead

NCT05097599Phase 2Terminated

StrataPATH™ (Precision Indications for Approved Therapies)

Role: lead

NCT04087018Phase 1Completed

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Role: collaborator

NCT05082701Terminated

Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

Role: lead

NCT05312307Withdrawn

Strata EXPress™: A Study Using StrataEXP™ to Identify RNA-Expression Biomarkers in Advanced Cancer Patients

Role: lead

All 6 trials loaded